Gyre Therapeutics (GYRE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GYRE Gyre Therapeutics

Watchlist

12.295
-0.365-2.88%

Trading Dec 31 13:02 ET

1.06BMarket Cap-8.42P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Gyre Therapeutics Entered Into Open Market Sale Agreement, May Offer & Sell Shares Of Common Stock Of Up To $50M From Time To Time
BenzingaNov 27, 2024 16:24 ET
Gyre Therapeutics Reports Q3 2024 Financial Results and Strategic Updates
TipRanksNov 14, 2024 23:37 ET
Express News | Gyre Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing
ReutersNov 14, 2024 16:40 ET
Express News | Gyre Therapeutics Shares Are Trading Lower After the Company Reported a Year-over-year Decline in Q3 Financial Results
BenzingaNov 13, 2024 14:03 ET
Gyre Therapeutics | 8-K: Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
SECNov 13, 2024 12:54 ET
Earnings Flash (GYRE) GYRE THERAPEUTICS Posts Q3 Revenue $25.5M
MT NewswiresNov 13, 2024 06:01 ET

Comments

108S

Jul 16, 2024 18:53

$Gyre Therapeutics (GYRE.US)$ sell or hold?

Jaguar8

May 30, 2024 15:11

NEWS

$Gyre Therapeutics (GYRE.US)$
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics (Nasdaq: GYRE), a biotech firm specializing in anti-fibrotic treatments, has received approval from China's NMPA for its Investigational New Drug (IND) application for F230. This drug, a selective endothelin receptor antagonist, is aimed at treating pulmonary arterial hypertension (PAH), a severe and progressive diso...

108S

May 29, 2024 08:33

$Gyre Therapeutics (GYRE.US)$Gyre Therapeutics Expects Addition To Russell - moomoo

Moomoo Recap US

Jan 22, 2024 15:13

Columns Wall Street Street | Great Day For Volume Stocks on Fresh Index Records

RECAP
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...

Kevin Travers

Jan 22, 2024 09:51

Columns BiotTech Rises with the Index Tide

After two major indexes reached all-time highs, pharmaceutical stocks for companies in drug trials were caught up in the energy and rocketed forward. The largest gainers were $Spyre Therapeutics (SYRE.US)$, up 26% Monday morning, and $Gyre Therapeutics (GYRE.US)$ +10%.
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...

Heat List

Overall

No Data